CRISPR Therapeutics AG (CRSP) is a Biotechnology company in the Healthcare sector, currently trading at $56.86. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CRSP = $65 (+14.3% upside).
Valuation: CRSP trades at a trailing Price-to-Earnings (P/E) of -8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.36.
Financials: revenue is $4M, +28286.1%/yr average growth. Net income is $582M (loss), growing at -40.3%/yr. Net profit margin is -16569.8% (negative). Gross margin is -6537% (+18649.7 pp trend).
Balance sheet: total debt is $395M against $1.9B equity (Debt-to-Equity (D/E) ratio 0.21, conservative). Current ratio is 13.32 (strong liquidity). Debt-to-assets is 17.4%. Total assets: $2.3B.
Analyst outlook: 22 / 38 analysts rate CRSP as buy (58%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 88/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 27/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
